Johnson & Johnson Drops 2.7% as 3.6% MedTech Growth Undercuts Raised Outlook
Updated
Updated · Trefis · Jul 16
Johnson & Johnson Drops 2.7% as 3.6% MedTech Growth Undercuts Raised Outlook
3 articles · Updated · Trefis · Jul 16
Summary
Johnson & Johnson shares fell 2.7% after earnings, even though the company beat revenue and profit estimates and lifted its full-year operational sales growth forecast to 6.5%-7.1%.
3.6% operational sales growth in MedTech drove the selloff, with cardiovascular weakness standing out as Abiomed heart-pump sales fell 2% and electrophysiology growth slowed to 3.1%.
Pharma remained the clear bright spot: overall operational sales rose 5.6%, TREMFYA sales jumped 71%, and DARZALEX grew nearly 18% to more than $4 billion.
That split sharpened investor concern that J&J's two-engine growth model is becoming overly dependent on Innovative Medicine, with stronger pharma performance masking softer MedTech assumptions.
The key question for the stock is whether MedTech—especially cardiovascular—rebounds, because a prolonged slowdown would weaken the case for J&J's balanced post-restructuring growth story.